Erik Singleton | Senior Director- Supply Chain Strategy Consulting
North Highland

Advanced Therapies USA 2025 - Day 1 @ 14:55

Scaling to one million patients: Cross-industry lessons for cell & gene therapy

Gene-modified cell therapies remain trapped in a high-cost, low-throughput paradigm, with ~40,000 patients treated to date versus the million-plus we must reach in the next decade. Solving the challenge demands new thinking. By fusing advanced analytics and agentic AI with proven playbooks from retail/CPG, automotive, agriculture, and fashion industries, we can compress vein-to-vein time, reduce costs, and enable quality at scale. 

This session distils those insights into a five-step roadmap—people, process, data, tech, culture—to develop a scalable, adaptive value chain ready for the next million patients.

Frank Orlowski, Managing Director, Supply Chain Life Sciences Practice, North Highland

×

Frank Orlowski / Scaling to one million patients: Cross-industry lessons for cell & gene therapy

Frank Orlowski, Managing Director, Supply Chain Life Sciences Practice,
North Highland

Frank Orlowski is a Managing Director in North Highland’s Supply Chain Life Sciences practice, based in NYC. He has more than 25 years of experience in the pharmaceutical industry, including senior leadership roles at Pfizer. Frank specializes in manufacturing cost optimization, strategic growth...

CloseMore

Erik Singleton, Senior Director- Supply Chain Strategy Consulting, North Highland

×

Erik Singleton / Scaling to one million patients: Cross-industry lessons for cell & gene therapy

Erik Singleton, Senior Director- Supply Chain Strategy Consulting,
North Highland

Supply Chain Practice Lead for North Highland with over 15 years of experience in Supply Chain including process improvement, supply chain strategy, digital transformation across life sciences companies. Leading manufacturing and supply optimization across CGT clients – big and small – with a focus ...

CloseMore